Clinical Study

Mirati 849-01- A Phase 1/2 Multiple Expansion Cohort Trial Of Mrtx849 In Patients With Advanced Solid Tumors With Kras G12c Mutation

Posted Date: Aug 5, 2020

  • Investigator: Davendra Sohal
  • Specialties: Cancer, Colorectal Cancer, Lung Cancer, Oncology
  • Type of Study: Drug

This is a multi-center, Phase 1/2, multiple expansion cohort trial evaluating the safety, PK, metabolites, PD and clinical activity/efficacy of MRTX849 in patients with advanced solid tumor malignancies with KRAS G12C mutation. The primary endpoints of this study are Overall response rate and progression free survival.

Criteria:

To Be Eligible: Must Have Histologically Confirmed Diagnosis Of A Solid Tumor Malignancy With Kras G12c Mutation, Unresectable Or Metastatic Disease, Life Expectancy Of At Least 3 Months, Ecog 0 Or 1, No Serious Illness, Uncontrolled Inter-Current Illness, Psychiatric Illness, Active Or Uncontrolled Infection, Or Other Medical History That May Interfere With Participation Or Results

Keywords:

Phase 1, Advanced Solid Tumor

For More Information:

Uc Cancer Center
513-584-7698
cancer@uchealth.com


  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at ResearchStudies@UCHealth.com or (513) 245-3417.